(635 days)
Estrogen Receptor Clone 6F11 (ER 6F11) Mouse Monoclonal antibody is intended for laboratory use to qualitatively identify estrogen receptor (ER) antigen in sections of formalin fixed, paraffin embedded breast cancer tissue by immunohistochemistry methods. Estrogen Receptor Clone 6F11 specifically binds to the ER antigen located in the nucleus of ER positive normal and neoplastic cells.
Estrogen Receptor Clone 6F1 I is indicated as an aid in the management, prognosis and predication of therapy outcome of breast cancer. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by qualified pathologist.
Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ and the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ are optimized for use on the Leica Biosystems Bond III staining platform using the Bond Polymer Refine Detection Kit.
Estrogen Receptor Clone 6F11 is a mouse anti-human monoclonal antibody produced as a tissue culture supernatant. This antibody is utilized to perform a semi-quantitative immunohistochemical (IHC) assay to identify estrogen receptor (ER) expression in human breast cancer tissue routinely processed and paraffin-embedded for histological examination.
Estrogen Receptor Clone 6F11 primary antibody is provided in two formats, a Bond™ Ready-to-Use format (product code PA0151 (7mL) and PA0009 (30 mL)) and a concentrated liquid format (product code NCL-L-ER-6F11 (1mL) and is optimally diluted for use on the automated Bond System (Bond III ) in combination with Bond Polymer Refine Detection kit.
Total protein concentration for Estrogen Receptor clone 6F11 is approximately 3.8 g/L. The immunoglobulin concentration is approximately 75 mg/L.
The Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra" is recommended for use at a dilution of 1 in 50 when diluted in Bond Antibody Diluent (AR9352).
The Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ is a tissue culture supernatant prepared at a working immunoglobulin concentration of 0.88 µg/mL. It is supplied in Tris buffered saline with carrier protein, containing 0.35% ProClin™ 950 as a preservative.
Acceptance Criteria and Device Performance for Estrogen Receptor Clone 6F11
The Leica Biosystems Estrogen Receptor Clone 6F11 (ER 6F11) primary antibody, in both Ready-to-Use (PA0151) and Liquid Concentrate (NCL-L-ER-6F11) formats, demonstrated performance across several studies to meet acceptance criteria for its intended use in immunohistochemistry for ER antigen identification in breast cancer tissue.
1. Table of Acceptance Criteria and Reported Device Performance
The provided document details various performance studies rather than explicit, pre-defined acceptance criteria with specific thresholds for each metric. However, the data presented strongly implies what would be considered acceptable performance for a device seeking governmental approval, particularly regarding reproducibility and correlation with existing methods and clinical outcomes.
Based on the studies, the implicit acceptance criteria for the device revolve around demonstrating high agreement in various precision and reproducibility studies, and acceptable clinical performance (sensitivity, specificity, PPV, NPV) when compared to a "gold standard."
Summary Table of Reported Device Performance against Implicit Acceptance Criteria:
| Study Type / Metric | Implicit Acceptance Criteria (Indicative) | Reported Device Performance (Leica Device) | Formats Studied |
|---|---|---|---|
| Clinical Outcome Study (Calgary Cohort) | Ready-to-Use (PA0151) | ||
| Inter-observer Kappa (ER Status) | High agreement (e.g., Kappa > 0.6) | 0.67 to 0.83 ("almost perfect agreement") | Ready-to-Use (PA0151) |
| Intra-observer Kappa (ER Status) | High agreement (e.g., Kappa > 0.8) | 0.91 ("almost perfect agreement") | Ready-to-Use (PA0151) |
| Univariate Kaplan-Meier HR (ER Status) | Statistically significant difference in survival between ER+ and ER- groups (p < 0.05) | HR: 0.24 (0.14-0.43), p < 0.0001 (Figure 2) | Ready-to-Use (PA0151) |
| Multivariate Cox Model HR (ER Status) | Statistically significant prognostic value (p < 0.05) | HR: 0.39 (0.19-0.78), p = 0.008 (Figure 3) | Ready-to-Use (PA0151) |
| Sensitivity (vs. LBA Gold Standard) | High (e.g., > 0.90) | 0.97 (Figure 4) | Ready-to-Use (PA0151) |
| Specificity (vs. LBA Gold Standard) | Adequate (e.g., > 0.40) | 0.44 (Figure 4) | Ready-to-Use (PA0151) |
| PPV (vs. LBA Gold Standard) | High (e.g., > 0.90) | 0.96 (Figure 4) | Ready-to-Use (PA0151) |
| NPV (vs. LBA Gold Standard) | Adequate (e.g., > 0.60) | 0.70 (Figure 4) | Ready-to-Use (PA0151) |
| Precision Studies (TMA) | Overall, Positive, and Negative Percent Agreement with high confidence intervals (e.g., > 90%) | All precision studies reported 100% OPA, PPA, NPA with tight 95% CIs (e.g., 97-100% range) | Both formats |
| Between Observer Precision (TMA) | High Overall Percent Agreement (OPA) (e.g., > 90%) | 95% (PA0151, Obs1-Obs2/Obs3), 100% (PA0151, Obs2-Obs3), 98.33% (PA0151, All Obs) | Both formats |
| 89.47% (NCL-L-ER-6F11, Obs1-Obs2), 94.74% (NCL-L-ER-6F11, Obs1-Obs3/Obs2-Obs3), 96.49% (NCL-L-ER-6F11, All Obs) | Left panel for PA0151, right for NCL-L-ER-6F11 | ||
| Reproducibility Studies (Whole Tissue Sections) | Overall, Positive, and Negative Percent Agreement with high confidence intervals (e.g., > 90%) | Varies by site/comparison, generally high (e.g., 88.89% - 100% OPA), but some lower bounds on CIs (e.g., 72.71% NPA for Site A PA0151 overall) | Both formats |
| Inter-Platform Comparison Study | High Overall, Positive, and Negative Percent Agreement when compared to the reference standard device | Overall PA: 96.73%, Positive PA: 98.37%, Negative PA: 90.16% (95% CI reported) | Liquid Concentrate (NCL-L-ER-6F11) vs. Ready-to-Use (PA0151) |
| Stability Studies | Intensity Score and Proportion Score identical to control for variable ER expression in breast cancer cases. | Reported with 18 months shelf-life via accelerated testing, ongoing real-time testing. | All three product formats |
2. Sample Size Used for the Test Set and Data Provenance
The document describes several distinct test sets:
- Clinical Outcome Study (Calgary Cohort):
- Sample Size: n=532 breast cancer patients (retrospectively analyzed); n=473 for univariate analysis; n=363 for multivariate analysis.
- Data Provenance: Retrospective, Calgary-based patient cohort (Canada), diagnosed between 1985 and 2000.
- Precision and Reproducibility Studies (TMA and Whole Tissue Sections): These studies used unspecified "breast cancer cases."
- Within-Run Precision (PA0151): 108 test data points (presumably cases or samples).
- Within-Instrument Precision (PA0151): 321 test data points.
- Between-Run Precision (PA0151): 180 test data points.
- Between Laboratory Precision (PA0151): 101 test data points from 3 investigational sites.
- Lot to Lot Precision (PA0151): 100 test data points using 3 reagent lots.
- Between Observer Precision (PA0151 & NCL-L-ER-6F11): 20 whole section breast cancer cases for each format (total 40 cases if both studies were distinct).
- Inter-Site Reproducibility (PA0151 & NCL-L-ER-6F11): 18 cases evaluated at 3 sites over 5 days (9 replicates per case).
- Lot to Lot Reproducibility (PA0151 & NCL-L-ER-6F11): 18 cases using 3 reagent lots.
- Inter-Platform Comparison Study:
- Sample Size: 306 invasive breast cancer specimens. An additional 452 cases were assessed to enrich the cohort, but the final reported results are for the 306 cases.
- Data Provenance: Clinical archives, from three independent US-based testing facilities. Specimens were formalin-fixed, paraffin-embedded.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
- Clinical Outcome Study (Calgary Cohort):
- Number of Experts: 3 observers scored slides (likely pathologists, though specific qualifications were not given beyond "observers").
- Qualifications: Not explicitly stated, but clinical outcome studies involving immunohistochemistry interpretation typically involve experienced pathologists.
- Precision, Reproducibility, and Inter-Platform Comparison Studies:
- Number of Experts: 3 observers/investigational sites are mentioned for between-observer and inter-site studies.
- Qualifications: Not explicitly stated beyond "observers" and "investigational sites." It's implied these are expert professionals (e.g., pathologists) involved in diagnostic interpretation.
4. Adjudication Method for the Test Set
- Clinical Outcome Study (Calgary Cohort): The scoring method was the "Allred scoring method." Cohen's Kappa statistic was used to quantify inter- and intra-observer reproducibility. While individual observer scores were compared, there is no explicit mention of an adjudication process (e.g., 2+1, 3+1) to establish a consensus ground truth solely among the experts for this specific test set. The ground truth for comparative effectiveness was primarily based on ligand-binding assay (LBA) and patient progression on tamoxifen.
- Precision, Reproducibility, and Inter-Platform Comparison Studies: For these studies, the "ground truth" often refers to a reference standard against which the test device is compared. For observer agreement studies, the "adjudication method" is the direct comparison of observer scores without necessarily establishing a final adjudicated truth.
- In the inter-platform comparison study, the "reference standard device" (Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ on the Bond III) effectively served as the de facto ground truth against which the Liquid Concentrate format was compared.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, And the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance
No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done in the context of human readers with vs. without AI assistance.
This document describes the validation of an immunohistochemistry (IHC) assay and its accompanying primary antibody, not an AI or digital pathology device meant to assist human readers. The studies focus on the performance and reproducibility of the IHC staining method itself.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
No, a standalone performance study in the context of an algorithm only was not done.
As noted above, this submission is for an IHC primary antibody and its associated staining platform, which is interpreted by human observers (pathologists). There is no mention of an algorithm or AI component in this device.
7. The Type of Ground Truth Used
The ground truth varied depending on the specific study:
- Clinical Outcome Study (Calgary Cohort):
- Ligand-binding assay (LBA): Used as a "gold standard" for calculating sensitivity, specificity, PPV, and NPV of the device.
- Patient progression on tamoxifen: Used as another "gold standard" for calculating diagnostic performance metrics, indicating real clinical outcome.
- Precision and Reproducibility Studies: For these studies, the "ground truth" was often the consensus or established score from a reference method or a designated expert, against which other measurements/observers were compared. For the between-observer studies, direct comparison of observer agreement served as the assessment.
- Inter-Platform Comparison Study: The Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ on the Bond III (the existing, approved format) served as the "reference standard test" or ground truth against which the Liquid Concentrate format was evaluated.
- Stability Studies: A "control score" for Intensity Score and Proportion Score was used as the ground truth.
8. The Sample Size for the Training Set
The document does not describe a "training set" in the context of a machine learning model, as the submission concerns an IHC assay and antibody, not an AI device.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as no training set for an AI model is described.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo for Leica Biosystems. The logo features the word "Leica" in a stylized, cursive font, with a thick, flowing line extending from the "L" to underline the entire word. Below "Leica" is the word "BIOSYSTEMS" in a bold, sans-serif font, with the letters evenly spaced.
MAY 1 9 2014
1 510(k) Summary
Traditional Premarket Notification Submission 510(k) Summary Prepared in accordance with 21 CFR 807.92
Assigned 510(k) number US K122556
2 Sponsor Name and Address
Leica Biosystems Newcastle, Ltd Balliol Business Park West Newcastle Upon Tyne, NE 12 8EW United Kingdom Establishment Registration: 3004859032
3 Contact
Barbara-Ann Conway-Myers, Ph.D. Senior Regulatory Affairs Specialist bacm@LeicaBiosystems.com 312-269-7205
4 Statement Prepared
July 8, 2012
5 Summary Revised:
April 15, 2014
Device Name б
| Trade (proprietary): | Estrogen Receptor Clone 6F11 |
|---|---|
| Common (usual): | Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for BondTMEstrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, NovocastraTM |
| Classification: | 21 CFR § 864.1869: Immunohistochemistry (IHC)Reagents and Kits (Class II) |
| FDA Device Code: | MYA |
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the logo for Leica Biosystems. The logo consists of the word "Leica" in a stylized, bold font, with a swooping line extending from the left side of the "L" to underneath the "a". Below the word "Leica", in a smaller, sans-serif font, is the word "BIOSYSTEMS". The logo is black and is set against a white background.
Panel:
88 (Pathology)
7 Substantially Equivalent Predicate Device
| Device Name: | Estrogen Receptor Clone 6F11, formerly named Vision BioSystems Estrogen Receptor Clone 6F11 (ER 6F11) (change due to re-branding) |
|---|---|
| Device 510(k): | · K060227 |
8 Device Description
Estrogen Receptor Clone 6F11 is a mouse anti-human monoclonal antibody produced as a tissue culture supernatant. This antibody is utilized to perform a semi-quantitative immunohistochemical (IHC) assay to identify estrogen receptor (ER) expression in human breast cancer tissue routinely processed and paraffin-embedded for histological examination.
Estrogen Receptor Clone 6F11 primary antibody is provided in two formats, a Bond™ Ready-to-Use format (product code PA0151 (7mL) and PA0009 (30 mL)) and a concentrated liquid format (product code NCL-L-ER-6F11 (1mL) and is optimally diluted for use on the automated Bond System (Bond III ) in combination with Bond Polymer Refine Detection kit.
Total protein concentration for Estrogen Receptor clone 6F11 is approximately 3.8 g/L. The immunoglobulin concentration is approximately 75 mg/L.
The Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra" is recommended for use at a dilution of 1 in 50 when diluted in Bond Antibody Diluent (AR9352).
The Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ is a tissue culture supernatant prepared at a working immunoglobulin concentration of 0.88 µg/mL. It is supplied in Tris buffered saline with carrier protein, containing 0.35% ProClin™ 950 as a preservative.
9 Test Principle
Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody, ER), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.
{2}------------------------------------------------
Image /page/2/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below "Leica" is the word "BIOSYSTEMS" written in a sans-serif font. The logo is in black and white.
A schematic diagram of the immunohistochemical staining technique using a polymer detection system is shown in figure 1 and described below.
Image /page/2/Picture/2 description: The image shows a diagram of a DAB staining process. The DAB molecules are shown as a chain of brown circles. The DAB molecules are binding to a secondary antibody, which is bound to a primary antibody. The primary antibody is bound to a tissue antigen.
Figure 1. Schematic diagram of the immunohistochemical staining technique using a polymer detection system to detect the primary antibody.
Estrogen Receptor Clone 6F11 is recommended for use in an immunohistochemical procedure, which allows the qualitative identification by light microscopy of antigens in sections of formalin-fixed, paraffin-embedded tissue, via sequential steps with interposed washing steps. Prior to staining, endogenous peroxidase activity is blocked and sections are subjected to epitope retrieval. As indicated in figure 1, the section is subsequently incubated with the mouse primary antibody that binds with the human tissue antigen. A polymeric enzyme-conjugated secondary antibody that recognizes mouse immunoglobulins is used to detect the primary antibody. Sections are further incubated with the substrate/chromogen, 3,3' - diaminobenzidine (DAB), and DAB Substrate Buffer. Reaction with the peroxidase produces a visible brown precipitate at the antigen site. Sections are counterstained with hematoxylin and coverslipped. Results are interpreted using a light microscope.
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font, with a distinctive loop in the "L" and a dot over the "i". Below "Leica", in a smaller, sans-serif font, is the word "BIOSYSTEMS" in all capital letters. The logo is black against a white background.
10 Intended Use
For in vitro diagnostic use
Estrogen Receptor Clone 6F11 (ER 6F11) Mouse Monoclonal antibody is intended for laboratory use to qualitatively identify estrogen receptor (ER) antigen in sections of formalin fixed, paraffin embedded breast cancer tissue by immunohistochemistry method. Estrogen Receptor Clone 6F11 specifically binds to the ER antigen located in the nucleus of ER positive normal and neoplastic cells.
Estrogen Receptor Clone 6F11 is indicated as an aid in the management, prognosis and predication of therapy outcome of breast cancer. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.
Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ and Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra "" are optimized for use on the Leica Biosystems Bond III staining platform using the Bond Polymer Refine Detection kit.
11 Performance Characteristics (Clinical)
Clinical Outcome Study (Calgary Cohort)
The Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ (PA0151) on the Bond III was tested in an independent clinical outcome study. In summary, the study used a retrospective Calgary-based patient cohort (n=532) composed of breast cancer patients diagnosed between 1985 and 2000, who were treated with primary adjuvant tamoxifen regardless of their ER and PR status. This cohort possesses several unique characteristics that lend to this study, including: it has greater than 5 years of follow-up; it was enriched for events to increase its statistical power; it contains ER negative patients so as to remove treatment selection bias.
To assess differences between methods in the study, the following statistical methods were evaluated ' and the outcomes described:
- The Cohen's Kappa statistic to quantify the ease of reproducibility of Allred scoring method (Inter- and Intra-Observer).
Results indicated that Inter-observer kappa for the Leica platform showed almost perfect agreement for ER, with x=0.67 between Observers 1 and 2, к=0.75 between Observers 1 and 3, and а к=0.83 between
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below "Leica" is the word "BIOSYSTEMS" written in a sans-serif, block letter font. The logo is black and white.
Observers 2 and 3. Slides were also rescored by Observer 1 three months after the original scoring and intra-observer kappa was calculated with almost perfect agreement of k=0.91.
- Univariate Kaplan-Meier and Multivariate Cox survival analysis using the Allred cutpoint for hormone receptor positivity to dichotomize patients into survival groups.
The univariate outcome is shown in figure 2.
Image /page/4/Figure/4 description: This image is a survival plot comparing disease-free survival probability over time in months for two groups, ER- and ER+. The ER- group has a significantly lower survival probability than the ER+ group, with the ER- group dropping to around 0.50 probability at 60 months, while the ER+ group remains above 0.75. The plot indicates a p-value of less than 0.0001 and a hazard ratio (HR) of 0.24 (0.14-0.43), with a total sample size of n=473.
Figure 2: Univariate Analysis for the Leica test Device
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows the logo for Leica Biosystems. The logo features the word "Leica" in a stylized, bold font, with a curved line extending from the bottom of the "L" to the "a". Below "Leica", the word "BIOSYSTEMS" is written in a smaller, sans-serif font. The entire logo is in black against a white background.
| Leica Device (n=363) | |||
|---|---|---|---|
| HR | 95% CI | p-value | |
| ER Status | 0.39 | (0.19-0.78) | 0.008 |
| Lymph Node Status | 3.18 | (1.88-5.37) | <0.001 |
| Tumor Grade | 3.15 | (1.84-5.38) | <0.001 |
| Tumor Size | 1.67 | (0.94-2.98) | 0.083 |
| HER2 Status | 1.13 | (0.38-3.33) | 0.823 |
Multivariate Cox models were analyzed along with lymph node status, tumour grade, tumour size and HER2 status. The model is shown in figure 3.
Figure 3: Multivariate model for the Leica test Device
- Measures of test performance; sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), were calculated. For these calculations, the ligand-binding assay (LBA) was used as the gold standard (figure 4). Also, the Leica assay and the LBA using progression on tamoxifen as the gold standard (figure 5) were calculated.
In this study, each measured test performance can be defined as:
Sensitivity is defined as the proportion of positive subjects correctly identified by the test.
Specificity is defined as the proportion of negative subjects correctly identified by the test.
PPV is defined as the proportion of subjects with a positive test result who were correctly diagnosed.
NPV is defined as the proportion of subjects with a negative test result who were correctly diagnosed.
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image shows the logo for Leica Biosystems. The logo consists of the word "Leica" in a stylized, bold font, with a swooping line underneath. Below the word "Leica" is the word "BIOSYSTEMS" in a smaller, sans-serif font. The logo is black and white.
Figures 4 and 5 show the results obtained.
| Leica Device | |
|---|---|
| Sensitivity | 0.97 |
| Specificity | 0.44 |
| PPV | 0.96 |
| NPV | 0.70 |
Figure 4: Measure of test performance (LBA = Gold Standard)
| Leica Device | LBA | |
|---|---|---|
| Sensitivity | 0.96 | 0.96 |
| Specificity | 0.16 | 0.16 |
| PPV | 0.82 | 0.84 |
| NPV | 0.52 | 0.44 |
Figure 5: Measure of test performance (Progression = Gold Standard)
Results from this study show that the test device, the Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ (PA0151) on the Bond III has excellent correlation in identification of the optimal clinical assay for the determination of endocrine treatment response in breast cancer.
Additionally,
The Leica platform used in the study was the Leica Bond III System. . •
The test device used in the study was the PA0151 (Estrogen Receptor Clone 6F11 Ready-to-Use . Primary Antibody for Bond™).
. The detection system used in the study was the Leica DS9800 Bond Polymer Refine Detection kit.
The staining protocol used in the study is as described below.
- The staining protocol used in the study was IHC Protocol F. ●
- Heat induced epitope retrieval using Bond Epitope Retrieval Solution 1 for 20 minutes was ● used.
{7}------------------------------------------------
Image /page/7/Picture/0 description: The image shows the logo for Leica Biosystems. The logo features the word "Leica" in a stylized, cursive font, with the letters connected. Below the word "Leica", in smaller, block letters, is the word "BIOSYSTEMS". The logo is black and white.
- Bond Polymer Refine Detection utilizes a novel controlled polymerization technology to prepare polymeric HRP-linker antibody conjugates. The detection system avoids the use of streptavidin and biotin, and therefore eliminates nonspecific staining as a result of endogenous biotin. Bond Polymer Refine Detection works as follows:
- The specimen is incubated with hydrogen peroxide to quench endogenous peroxidase . activity
- Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond"" is applied .
- A post primary antibody solution enhances penetration of the subsequent polymer ● reagent
- A poly-HRP anti-mouse/rabbit IgG reagent localizes the primary antibody ●
- The substrate chromogen, 3,3'- diaminobenzidine (DAB), visualizes the complex via a ● brown precipitate
- Hematoxylin (blue) counterstaining allows the visualization of cell .
All reagents and protocols used in this independent study were the same as that used in this 510K submission.
PRECISION RESULTS 12
Testing was initially conducted to assess within-run, within-instrument, between-run, betweenlaboratory and lot-to-lot precision using tissue micro-arrays (TMA) using the devices as described below.
Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ on the Bond III (Test 12.1 Device)
Precision results for the Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ on the Bond III are shown below.
12.1.1 Within Run Precision Study (intra assay - single instrument)
Testing was conducted on one SSA (1) [108 test data points with Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ (Lot 21825), 1 test slide with negative control antibody and 1 assay Control Slide] three times, over three different days.
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 81 | 0 |
| Negative | 0 | 27 | |
| Overall Percent Agreement (95% CI) | 100% (97.26-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (96.37-100) | ||
| Negative Percent Agreement (95% CI) | 100% (89.50-100) |
{8}------------------------------------------------
Image /page/8/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, bold font, with the letters connected in a cursive-like manner. Below "Leica" is the word "BIOSYSTEMS" written in a smaller, sans-serif font. The logo is black and appears against a white background.
12.1.2 Within Instrument Precision Study (inter assay - single Instrument)
Testing was conducted on three SSA's (1, 2, 3) [321 test data points with Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ (Lot 21825), 3 test slides with negative control antibody and 3 assay Control Slide] three times, over three different days.
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 241 | 0 |
| Negative | 0 | 80 | |
| Overall Percent Agreement (95% CI) | 100% (99.07-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (98.76-100) | ||
| Negative Percent Agreement (95% CI) | 100% (96.32-100) |
12.1.3 Between Run Precision Study (inter assay - day-to-day - single instrument)
Testing was conducted on one SSA (1) [180 test data points with Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ (Lot 21825), 1 test slide with negative control antibody and 1 assay Control Siide] five times, over five different days, performed over a twenty (20) day period.
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 135 | 0 |
| Negative | 0 | 45 | |
| Overall Percent Agreement (95% CI) | 100% (98.35-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (97.81-100) | ||
| Negative Percent Agreement (95% CI) | 100% (93.56-100) |
{9}------------------------------------------------
Image /page/9/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below "Leica", the word "BIOSYSTEMS" is written in block letters. The logo is black and white.
12.1.4 Between Laboratory Precision Study (site-to-site - inter assay - multiple instruments)
Testing was conducted on one SSA (1) [101 test data points with Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ (Lot 21825), 1 test slide with negative control antibody and 1 assay Control Slide] at 3 investigational sites (Sites A, B and C).
| Positive | Negative | ||
|---|---|---|---|
| Positive | 78 | 0 | |
| PA0151 (RTU) Bond III | Negative | 0 | 23 |
| Overall Percent Agreement (95% CI) | 100% (97.08-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (96.23-100) | ||
| Negative Percent Agreement (95% CI) | 100% (87.79-100) |
12.1.5 Lot to Lot Precision Study
Testing was conducted on one SSA (1) [100 test data points with Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™, 3 test slides with negative control antibody and 3 assay Control Slide] using three (3) independently manufactured reagent lots of the test device (Lot 1 = 21825; Lot 2 = 21866; Lot 3 = 21867).
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 75 | 0 |
| Negative | 0 | 25 | |
| Overall Percent Agreement (95% CI) | 100% (97.05-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (96.08-100) | ||
| Negative Percent Agreement (95% CI) | 100% (88.71-100) |
{10}------------------------------------------------
Image /page/10/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a bold, stylized font, with a curved line underlining the word. Below the word "Leica", the word "BIOSYSTEMS" is written in a smaller, sans-serif font. The logo is black and white.
12.1.6 Between Observer Precision Study
Between observer precision testing was evaluated between 3 observers at 1 investigational site (Site A). Twenty (20) whole section breast cancer cases consisting of 5x Positive (Strong Intensity Expression) Profile Breast Carcinoma cases, 5x Positive (Medium Intensity Expression) Profile Breast Carcinoma cases, 5x Positive (Weak Intensity Expression) Profile Breast Carcinoma cases and 5x Negative Profile Breast Carcinoma were used.
Between observer agreement between Observer 1 and Observer 2 was 95% (19/20).
| Observer 1 | |||
|---|---|---|---|
| Positive | Negative | ||
| Observer 2 | Positive | 14 | 0 |
| Negative | 1 | 5 | |
| Overall Percent Agreement (95% CI) | 95% (75.13-99.87) | ||
| Positive Percent Agreement (95% CI) | 93.33% (68.05-99.83) | ||
| Negative Percent Agreement (95% CI) | 100% (54.93-100) |
Between observer agreement between Observer 1 and Observer 3 was 95% (19/20).
| Observer 1 | |||
|---|---|---|---|
| Positive | Negative | ||
| Observer 3 | Positive | 14 | 0 |
| Negative | 1 | 5 | |
| Overall Percent Agreement (95% CI) | 95% (75.13-99.87) | ||
| Positive Percent Agreement (95% CI) | 93.33% (68.05-99.83) | ||
| Negative Percent Agreement (95% CI) | 100% (54.93-100) |
Between observer agreement between Observer 2 and Observer 3 was 100% (20/20).
| Observer 2 | |||
|---|---|---|---|
| Positive | Negative | ||
| Observer 3 | Positive | 14 | 0 |
| Negative | 0 | 6 | |
| Overall Percent Agreement (95% CI) | 100% (86.09-100) | ||
| Positive Percent Agreement (95% CI) | 100% (80.74-100) | ||
| Negative Percent Agreement (95% CI) | 100% (60.70-100) |
{11}------------------------------------------------
Image /page/11/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below "Leica" is the word "BIOSYSTEMS" written in a blocky, sans-serif font. The logo is black and white.
Between observer agreement between Observer 2 and Observer 3 was 98.33% (59/60).
| All Observers | All Observers | ||
|---|---|---|---|
| Positive | Negative | ||
| All Observers | Positive | 42 | 1 |
| Negative | 0 | 17 | |
| Overall Percent Agreement (95% CI) | 98.33% (91.06-99.96) | ||
| Positive Percent Agreement (95% CI) | 100% (93.12-100) | ||
| Negative Percent Agreement (95% CI) | 94.44% (72.71-99.86) |
12.2 Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ on the Bond III (Test Device)
Precision results for the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ on the Bond III are shown below.
12.2.1 Within Run Precision Study (intra assay - single instrument)
Testing was conducted on one SSA (1) [104 test data points with the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ (Lot 6021831), 1 test slide with negative control antibody and 1 assay Control Slide] three times, over three different days.
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11(Concentrate) Bond III | Positive | 79 | 0 |
| Negative | 0 | 25 | |
| Overall Percent Agreement (95% CI) | 100% (97.16-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (96.28-100) | ||
| Negative Percent Agreement (95% CI) | 100% (88.71-100) |
{12}------------------------------------------------
Image /page/12/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below the word "Leica" is the word "BIOSYSTEMS" written in a sans-serif, all-caps font. The logo is black and white.
12.2.2 Within Instrument Precision Study (inter assay - single Instrument)
Testing was conducted on three SSA's (1, 2, 3) [313 test data points with the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ (Lot 6021831), 3 test slides with negative control antibody and 3 assay Control Slide] three times, over three different days.
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11(Concentrate) Bond III | Positive | 236 | 1 |
| Negative | 0 | 76 | |
| Overall Percent Agreement (95% CI) | 99.68% (98.23-99.99) | ||
| Positive Percent Agreement (95% CI) | 100% (98.74-100) | ||
| Negative Percent Agreement (95% CI) | 98.70% (92.96-99.97) |
12.2.3 Between Run Precision Study (inter assay - day-to-day - single instrument)
Testing was conducted on one SSA (1) [175 test data points with the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ (Lot 6021831), 1 test slide with negative control antibody and 1 assay Control Slide] five times, over five different days, performed over a twenty (20) day period.
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11(Concentrate) Bond III | Positive | 132 | 0 |
| Negative | 0 | 43 | |
| Overall Percent Agreement (95% CI) | 100% (98.30-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (97.76-100) | ||
| Negative Percent Agreement (95% CI) | 100% (93.27-100) |
{13}------------------------------------------------
Image /page/13/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below the word "Leica" is the word "BIOSYSTEMS" written in a sans-serif, all-caps font. The logo is black and white.
12.2.4 Between Laboratory Precision Study (site-to-site - inter assay - multiple instruments)
Testing was conducted on one SSA (1) [104 test data points with the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ (Lot 6021831), 1 test slide with negative control antibody and 1 assay Control Slide] at 3 investigational sites (Sites A, B and C).
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11 | Positive | 78 | 0 |
| (Concentrate) Bond III | Negative | 0 | 26 |
| Overall Percent Agreement (95% CI) | 100% (97.16-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (96.23-100) | ||
| Negative Percent Agreement (95% CI) | 100% (89.12-100) |
12.2.5 Lot to Lot Precision Study
Testing was conducted on one SSA (1) [107 test data points with the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™, 3 test slides with negative control antibody and 3 assay Control Slide] using three (3) independently manufactured reagent lots of the test device (Lot 1 = 6021831; Lot 2 = 6021836; Lot 3 = 6021857).
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11(Concentrate) Bond III | Positive | 80 | 0 |
| Negative | 0 | 27 | |
| Overall Percent Agreement (95% CI) | 100% (97.24-100.00) | ||
| Positive Percent Agreement (95% CI) | 100% (96.32-100) | ||
| Negative Percent Agreement (95% CI) | 100% (89.50-100) |
12.2.6 Between Observer Precision Study
Between observer precision testing was evaluated between 3 observers at 1 investigational site (Site A). Twenty (20) whole section breast cancer cases consisting of 5x Positive (Strong Intensity Expression) Profile Breast Carcinoma cases, 5x Positive (Medium Intensity Expression) Profile Breast Carcinoma cases, 5x Positive (Weak.Intensity Expression) Profile Breast Carcinoma cases and 5x Negative Profile Breast Carcinoma were used.
Between observer agreement between Observer 1 and Observer 2 was 89.47% (17/19). One case was omitted as it was reported by observer 1 as invasive tumour, while observer 2 reported
{14}------------------------------------------------
Image /page/14/Picture/0 description: The image shows the logo for Leica Biosystems. The logo consists of the word "Leica" in a stylized, cursive font, with a thick underline. Below the word "Leica" is the word "BIOSYSTEMS" in a smaller, sans-serif font. The logo is black and white.
this as ductal carcinoma in-situ (DCIS) only, indicating a difference in the primary diagnosis of breast cancer.
| Observer 1 | |||
|---|---|---|---|
| Positive | Negative | ||
| Observer 2 | Positive | 12 | 0 |
| Negative | 2 | 5 | |
| Overall Percent Agreement (95% CI) | 89.47% (66.86-98.70) | ||
| Positive Percent Agreement (95% CI) | 85.71% (57.19-98.22) | ||
| Negative Percent Agreement (95% CI) | 100% (54.93-100) |
Between observer agreement between Observer 1 and Observer 3 was 94.74% (18/19). One case was omitted as it was reported by observer 1 as invasive tumour, while observer 2 reported this as ductal carcinoma in-situ (DCIS) only, indicating a difference in the primary diagnosis of breast cancer.
| Observer 1 | |||
|---|---|---|---|
| Positive | Negative | ||
| Observer 3 | Positive | 13 | 0 |
| Negative | 1 | 5 | |
| Overall Percent Agreement (95% CI) | 94.74% (73.97-99.87) | ||
| Positive Percent Agreement (95% CI) | 92.86% (66.13-99.82) | ||
| Negative Percent Agreement (95% CI) | 100% (54.93-100) |
Between observer agreement between Observer 2 and Observer 3 was 94.74% (18/19). One case was omitted as both observers reported a single case as ductal carcinoma in-situ (DCIS) only.
| Observer 2 | |||
|---|---|---|---|
| Positive | Negative | ||
| Observer 3 | Positive | 12 | 1 |
| Negative | 0 | 6 | |
| Overall Percent Agreement (95% CI) | 94.74% (73.97-99.87) | ||
| Positive Percent Agreement (95% CI) | 100% (77.91-100) | ||
| Negative Percent Agreement (95% CI) | 85.71% (42.13-99.64) |
{15}------------------------------------------------
Image /page/15/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font, with the letters connected. Below "Leica", the word "BIOSYSTEMS" is written in a sans-serif, all-caps font. The logo is black and appears on a white background.
Between observer agreement between Observer 1, Observer 2 and Observer 3 was 96.49% (55/57). One case was omitted as it was reported by observer 1 as invasive tumour, while observer 2 and 3 reported this as ductal carcinoma in-situ (DCIS) only, indicating a difference in the primary diagnosis of breast cancer.
| All Observers | |||
|---|---|---|---|
| Positive | Negative | ||
| All Observers | Positive | 38 | 1 |
| Negative | 1 | 17 | |
| Overall Percent Agreement (95% CI) | 96.49% (87.89-99.57) | ||
| Positive Percent Agreement (95% CI) | 97.44% (86.52-99.94) | ||
| Negative Percent Agreement (95% Cl) | 94.44% (72.71-99.86) |
REPRODUCIBILITY RESULTS (whole tissue section testing) 13
Based on the results obtained in precision testing using TMA material above, further reproducibility testing using whole tissue sections on the Bond III .
13.1 Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond'''' (Test Device)
Precision results for the Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ on the Bond III are shown below.
13.1.1 Inter-Site Reproducibility
Inter-site reproducibility testing of the Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond "" was evaluated at 3 investigational sites (Sites A, B and C) on whole tissue sections. The test cohort consisted of 18 cases. Testing was performed over a span of 5 nonconsecutive days (Day1, Day3, Day 5), with each site staining a full set of cases on each day. This provided 9 replicates of 18 cases.
Results for Inter-Site reproducibility are presented by overall (3 sites combined), single site and site to site.
Negative percent agreement, positive agreement and overall agreement for each site has been reported.
{16}------------------------------------------------
Image /page/16/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below "Leica" is the word "BIOSYSTEMS" written in a sans-serif, all-caps font. The logo is black and white.
Overall (3 sites combined)
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 96 | 6 |
| Negative | 3 | 57 | |
| Overall Percent Agreement (95% CI) | 94.44% (89.72-97.43) | ||
| Positive Percent Agreement (95% CI) | 96.97% (91.40-99.37) | ||
| Negative Percent Agreement (95% CI) | 90.48% (80.41-96.42) |
Site A Results
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 35 | 1 |
| Negative | 1 | 17 | |
| Overall Percent Agreement (95% CI) | 96.30% (87.25-99.55) | ||
| Positive Percent Agreement (95% CI) | 97.22% (85.47-99.93) | ||
| Negative Percent Agreement (95% CI) | 94.44% (72.71-99.86) |
Site B Results
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 33 | 1 |
| Negative | 0 | 20 | |
| Overall Percent Agreement (95% CI) | 98.15% (90.11-99.95) | ||
| Positive Percent Agreement (95% CI) | 100% (91.32-100) | ||
| Negative Percent Agreement (95% CI) | 95.24% (76.18-99.88) |
.
{17}------------------------------------------------
Image /page/17/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized font, with the letters connected. Below the word "Leica" is the word "BIOSYSTEMS" written in a sans-serif font. The logo is black and white.
Site C Results
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 32 | 0 |
| Negative | 1 | 21 | |
| Overall Percent Agreement (95% CI) | 98.15% (90.11-99.95) | ||
| Positive Percent Agreement (95% CI) | 96.97% (84.24-99.92) | ||
| Negative Percent Agreement (95% CI) | 100% (86.71-100) |
Site A versus Site B
| Site A | |||
|---|---|---|---|
| Positive | Negative | ||
| Site B | Positive | 32 | 2 |
| Negative | 4 | 16 | |
| Overall Percent Agreement (95% CI) | 88.89% (77.37-95.81) | ||
| Positive Percent Agreement (95% CI) | 88.89% (73.94-96.89) | ||
| Negative Percent Agreement (95% CI) | 88.89% (65.29-98.62) |
{18}------------------------------------------------
Image /page/18/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized font, with the letters connected in a cursive style. Below the word "Leica", the word "BIOSYSTEMS" is written in a smaller, sans-serif font. The logo is black and white.
Site A versus Site C
| Site A | |||
|---|---|---|---|
| Positive | Negative | ||
| Site C | Positive | 32 | 0 |
| Negative | 4 | 18 | |
| Overall Percent Agreement (95% CI) | 92.59% (82.11-97.94) | ||
| Positive Percent Agreement (95% CI) | 88.89% (73.94-96.89) | ||
| Negative Percent Agreement (95% CI) | 100% (84.67-100) |
Site B versus Site C
| Site B | |||
|---|---|---|---|
| Positive | Negative | ||
| Site C | Positive | 31 | 1 |
| Negative | 3 | 19 | |
| Overall Percent Agreement (95% CI) | 92.59% (82.11-97.94) | ||
| Positive Percent Agreement (95% CI) | 91.18% (76.32-98.14) | ||
| Negative Percent Agreement (95% CI) | 95.00% (75.13-99.87) |
{19}------------------------------------------------
Image /page/19/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a cursive font, with the letters connected. Below the word "Leica", the word "BIOSYSTEMS" is written in a sans-serif font. The logo is black and white.
13.1.2 Lot to Lot Precision Study
Lot to lot reproducibility testing of the Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond" was evaluated at a single investigational site on whole tissue sections. The test cohort consisted of 18 cases. Testing was conducted using three (3) independently manufactured reagent lots (Lot 1 = 21825; Lot 2 = 21866; Lot 3 = 21867). This format provided 3 replicates of each slide (one for each reagent lot).
| Positive | Negative | ||
|---|---|---|---|
| PA0151 (RTU) Bond III | Positive | 32 | 1 |
| Negative | 1 | 20 | |
| Overall Percent Agreement (95% CI) | 96.30% (87.25-99.55) | ||
| Positive Percent Agreement (95% CI) | 96.97% (84.24-99.92) | ||
| Negative Percent Agreement (95% CI) | 95.24% (76.18-99.88) |
13.2 Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra" (Test Device)
Precision results for the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ on the Bond III are shown below.
13.2.1 Inter-Site Reproducibility
Inter-site reproducibility testing of the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ was evaluated at 3 investigational sites (Sites A, B and C) on whole tissue sections. The test cohort consisted of 18 cases. Testing was performed over a span of 5 non-consecutive days (Day1, Day3, Day 5), with each site staining a full set of cases on each day. This provided 9 replicates of 18 cases.
Results for Inter-Site reproducibility are presented by overall (3 sites combined), single site and site to site.
Negative percent agreement, positive agreement and overall agreement for each site has been reported.
{20}------------------------------------------------
Image /page/20/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below "Leica" is the word "BIOSYSTEMS" in a sans-serif font. The logo is black and white.
Overall (3 sites combined)
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11(Concentrate) Bond III | Positive | 111 | 0 |
| Negative | 6 | 45 | |
| Overall Percent Agreement (95% CI) | 96.30% (92.11-98.63) | ||
| Positive Percent Agreement (95% CI) | 94.87% (89.17-98.10) | ||
| Negative Percent Agreement (95% CI) | 100% (93.56-100) |
Site A Results
| Positive | Negative | |
|---|---|---|
| NCL-L-ER-6F11(Concentrate) Bond III | Positive39 | 0 |
| Negative0 | 15 | |
| Overall Percent Agreement (95% CI) | 100% (94.60-100) | |
| Positive Percent Agreement (95% CI) | 100% (92.61-100) | |
| Negative Percent Agreement (95% CI) | 100% (81.90-100) |
"
{21}------------------------------------------------
Image /page/21/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below "Leica" is the word "BIOSYSTEMS" written in a sans-serif, block letter font. The logo is black and white.
Site B Results
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11(Concentrate) Bond III | Positive | 35 | 1 |
| NCL-L-ER-6F11(Concentrate) Bond III | Negative | 1 | 17 |
| Overall Percent Agreement (95% CI) | 96.30% (87.25-99.55) | ||
| Positive Percent Agreement (95% CI) | 97.22% (85.47-99.93) | ||
| Negative Percent Agreement (95% CI) | 94.44% (72.71-99.86) |
Site C Results
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11 | Positive | 35 | 1 |
| (Concentrate) Bond III | Negative | 1 | 17 |
| Overall Percent Agreement (95% CI) | 96.30% (87.25-99.55) | ||
| Positive Percent Agreement (95% CI) | 97.22% (85.47-99.93) | ||
| Negative Percent Agreement (95% CI) | 94.44% (72.71-99.86) |
・
{22}------------------------------------------------
Image /page/22/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, cursive font. Below "Leica" is the word "BIOSYSTEMS" in a smaller, sans-serif font. The logo is in black and white.
Site A versus Site B
| Site A | |||
|---|---|---|---|
| Positive | Negative | ||
| Site B | Positive | 36 | 0 |
| Negative | 3 | 15 | |
| Overall Percent Agreement (95% CI) 94.44% (84.61-98.84) | |||
| Positive Percent Agreement (95% CI) 92.31% (79.13-98.38) | |||
| Negative Percent Agreement (95% CI) 100% (81.90-100) |
.
Site A versus Site C
| Site A | |||
|---|---|---|---|
| Positive | Negative | ||
| Site C | Positive | 36 | 0 |
| Negative | 3 | 15 | |
| Overall Percent Agreement (95% CI) | 94.44% (84.61-98.84) | ||
| Positive Percent Agreement (95% CI) | 92.31% (79.13-98.38) | ||
| Negative Percent Agreement (95% CI) | 100% (81.90-100) |
.
{23}------------------------------------------------
Image /page/23/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a cursive font, with the letters connected. Below the word "Leica", the word "BIOSYSTEMS" is written in a sans-serif font. The logo is black and white.
Site B versus Site C
| Site B | |||
|---|---|---|---|
| Positive | Negative | ||
| Site C | Positive | 34 | 2 |
| Negative | 2 | 16 | |
| Overall Percent Agreement (95% CI) | 92.59% (82.11-97.94) | ||
| Positive Percent Agreement (95% CI) | 94.44% (81.34-99.32) | ||
| Negative Percent Agreement (95% CI) | 88.89% (65.29-98.62) |
13.2.2 Lot to Lot Precision Study
Lot to lot reproducibility testing of the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ was evaluated at a single investigational site on whole tissue sections. The test cohort consisted of 18 cases. Testing was conducted using three (3) independently manufactured reagent lots (Lot 1 = 6021831; Lot 2 = 6021836; Lot 3 = 6021857). This format provided 3 replicates of each slide (one for each reagent lot).
| Positive | Negative | ||
|---|---|---|---|
| NCL-L-ER-6F11 | Positive | 32 | 0 |
| (Concentrate) Bond III | Negative | 1 | 21 |
| Overall Percent Agreement (95% CI) | 98.15% (90.11-99.95) | ||
| Positive Percent Agreement (95% CI) | 96.97% (84.24-99.92) | ||
| Negative Percent Agreement (95% CI) | 100% (86.71-100) |
. .
.
{24}------------------------------------------------
Image /page/24/Picture/0 description: The image shows the logo for Leica Biosystems. The logo consists of the word "Leica" in a stylized, cursive font, with a thick line underlining the word. Below the line, in smaller, block letters, is the word "BIOSYSTEMS". The logo is black and is set against a white background.
13.3 Precision Summary
In addition to the evaluation method and in keeping with standard pathological practice, all aspects of staining quality were assessed and reported for each case, i.e., staining intensity, proportion of cells staining, background staining, tissue morphology, staining of benign ductal cells, stromal cells, endothelial cells and lymphocytes.
Cases for reproducibility studies were selected with the following estrogen receptor expression; 6 negative, 6 around cut off (1-10% tumour staining; Allred proportion score of 2) and 6 positive cases (>10% tumour staining). Reproducibility studies have shown that for cases around the cut-off (1-10% tumour staining), a single pathologist has reproducibly estimated a similar percentage of cells staining between the three replicate slides. When all three pathologist percentage of cells staining scores are compared, it has shown that some variation in the number of cells estimated exists. This shows the limitations of a subjective method based on estimation alone.
In addition, small differences in the percentage of cells stained and then estimated by the same pathologist may be due to tumour heterogeneity. Multiple sections from each tissue block are required to perform reproducibility studies, with this process resulting in different cells being examined between each section. Small foci of tumour will invariably cut in/out of the tissue section and result in differences in interpretation. This phenomenon has been widely published and the concept is most effectively demonstrated by the micro-dissection of sentinel node tumour micro-metastases analysis (Weaver 2010).
Based on acceptance and approval of the Test Device Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond 111, this device is now considered the Reference Standard Test for the further Inter-Platform Comparison Studies.
14 Inter-Platform Comparison Study
An inter-platform comparison study was performed at three independent US based testing facilities. Comparative data between the reference standard device Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ on the Bond III and Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, NovocastraTM on the Bond III.
Blinding and randomization was used throughout the evaluation to reduce bias. Screeners were blinded to the test used.
The sample types (specimens) used in clinical evaluation were whole tissue sections, formalin fixed, and paraffin embedded invasive breast cancer cases. The specimens utilized were obtained from clinical archives, representative of the intended population, samples appropriately handled in the clinical environment, and met all local and national institutional review board (IRB) ethical approval for use in clinical evaluation studies.
Positive procedural controls were performed to validate assay performance. Procedural controls were not used for statistical analysis.
{25}------------------------------------------------
Image /page/25/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, bold font. Below "Leica" is the word "BIOSYSTEMS" written in a smaller, sans-serif font. The logo is black and white.
Negative controls were performed on the same tissues as the test article. The negative controls were not used for statistical analysis.
14.1 Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ on the Bond III (Test Device)
Inter-Platform comparison study results for Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ on the Bond III compared against the reference standard test using the primary evaluation method are shown below.
| Reference Standard Test | |||
|---|---|---|---|
| Positive | Negative | ||
| NCL-L-ER-6F11(Concentrate) Bond III | Positive | 241 | 6 |
| Negative | 4 | 55 | |
| Overall Percent Agreement (95% CI) | 96.73% (94.07-98.42%) | ||
| Positive Percent Agreement (95% CI) | 98.37% (95.87-99.55) | ||
| Negative Percent Agreement (95% CI) | 90.16% (79.81-96.30) |
Based on the results, all documented evidence supports substantial equivalence between the both the concentrated and RTU formats of ER 6F11 on the Bond III.
14.2 Inter-Platform Comparison Study Summary
The total cohort included for the Inter-Platform comparison study was three hundred and six (306) invasive breast cancer specimens.
A requirement set by FDA for the cohort to include a minimum of 10% of test cases that express estrogen receptor around the cut off (1-10%), when assessed by the reference standard device, was not met. The total overall percentage of cases in this category was 7.5% (23/306). Assessment of an additional 452 cases was undertaken in an attempt to enrich the cohort to 10%.
Recent publications (Hicks DH, Zhang Z, et al), in which 1700 consecutive invasive breast cancer patients were assessed for ER status, indicated that only 2% of cases expressed estrogen in the 1-10% range. This indicates that these tumours are not common and that the 7.5% of cases assessed within this cohort is representative of almost 4 times the normal population.
Additionally, differences in the percentage of cells stained and then estimated by the same pathologist between test devices may be due to tumour heterogeneity. Multiple sections from each tissue block are required to perform comparison studies, with this process resulting in different cells being examined between each section. Foci of tumour will invariably cut in/out of the tissue section and result in differences in interpretation. This phenomenon has been widely
{26}------------------------------------------------
Image /page/26/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, bold font. Below "Leica" is the word "BIOSYSTEMS" written in a smaller, sans-serif font. The logo is black and white.
published and the concept is most effectively demonstrated by the micro-dissection of sentinel node tumour micro-metastases analysis (Weaver 2010).
In addition to the evaluation method and in keeping with standard pathological practice, all aspects of staining quality were assessed and reported for each case, i.e., staining intensity, proportion of cells staining, background staining, tissue morphology, staining of benign ductal cells, stromal cells, endothelial cells and lymphocytes.
Stability Summary 15
Stability studies were performed using three independently manufactured lots of Estrogen Receptor Clone 6F11 for the different formats of the product listed below.
- Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ -- 7 ml PA0151 .
- Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ 30 mL PA0009 .
- Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ 1 mL NCL-L-. ER-6F11
Testing was performed on breast cancer tissue sections that expressed estrogen receptor at a high (3), medium (2), low (1) and negative (0) intensity (Intensity Score) and on normal breast tissue.
Acceptance criteria is based on; Test case passes if the Intensity Score and the Proportion Score (≥ 1% of turnour cell nuclei staining = Positive; < 1% of tumour cell nuclei staining = Negative) are identical for each of the test estrogen expressive breast cancer cases used when compared to a control score. A test will fail if this criteria is not met.
Stability claims to date, based on accelerated testing for the three listed product formats above is:
- . 18 months (545 days) from the point of manufacture when stored at 2 – 8 °C.
Real time stability data (18 months) will be tested for the Ready-to-Use formats of the product on the 20 May 2014. Real time stability data (18 months) will be tested for the Liquid concentrate format of the product on the 17 June 2014.
Transportation stress testing and In-Use stability testing has additionally been conducted and shown to be acceptable.
The table below shows a summary of the stability testing to date and indicates time point for continued testing.
Leica Biosystems Newcastle, Ltd.
ﻟ
{27}------------------------------------------------
Image /page/27/Picture/0 description: The image shows the Leica Biosystems logo. The word "Leica" is written in a stylized font, with the letters tilted and connected. Below the word "Leica", the word "Biosystems" is written in a smaller, sans-serif font. The logo is oriented vertically.
Stability Summary
| R Formats | Tissue | Number of Batches Tested | Scoring | Acceptance Criteria | Results | Next Real Time Test Point (Date & Timepoint) |
|---|---|---|---|---|---|---|
| Estrogen Receptor Clone 6F11 Ready-to-use Primary Antibody for BondTM,1mL PA0151 | Variable ER expression (IS) Breast CarcinomaHigh (Nuclear Intensity Score 3)Medium (Nuclear Intensity Score 2)Low ((Nuclear Intensity Score1)Negative (Nuclear Intensity Score 0)Normal breast | 3 | Scoring based on:Nuclear intensityscore (0 =Negative; 1 =Weak; 2 =Intermediate; 3 =Strong) &Proportion score | A test passes if theIntensity Score (IS)and the ProportionScore (PS) areidentical for each ofthe variable ER | Report issuedwith 18Months shelflife viaacceleratedtesting | 20/05/2014 -12 Months |
| Estrogen Receptor Clone 6F11 Ready-to-use Primary Antibody for BondTM,10mL PA0009 | Variable ER expression Breast CarcinomaHigh (Nuclear Intensity Score 3)Medium (Nuclear Intensity Score 2)Low ((Nuclear Intensity Score1)Negative (Nuclear Intensity Score 0)Normal breast | 3 | Proportion score(> 1% of tumourcell nuclei staining= Positive; < 1% oftumour cell nucleistaining =Negative) | expressive breastcarcinoma cores onthe TMA whencompared to theControl score. (PS | Report issuedwith 18Months shelflife viaacceleratedtesting | 20/05/2014-12 Months |
| Estrogen Receptor Clone 6F11 LiquidConcentrate Primary Antibody,NovocastraTM,NCL-L-ER-6F11 (1mL) for use on Bond | Variable ER expression Breast CarcinomaHigh (Nuclear Intensity Score 3)Medium (Nuclear Intensity Score 2)Low ((Nuclear Intensity Score1)Negative (Nuclear Intensity Score 0)Normal breast | 3 | score is notapplicable for thenormal breast core) | Report issuedwith 18Months shelflife viaacceleratedtesting | 17/06/2014-12 Months |
Page 28
{28}------------------------------------------------
Image /page/28/Picture/0 description: The image shows the logo for Leica Biosystems. The word "Leica" is written in a stylized, bold font, with a swooping line underlining it. Below the line, in smaller, block letters, is the word "BIOSYSTEMS". The logo is black and appears against a white background.
। ਦ Conclusions
Estrogen Receptor Clone 6F11, was determined to have excellent correlation for the determination of endocrine treatment response in breast cancer based on data performed in an independent Clinical Outcome Study (Calgary Cohort). This study also showed clinical correlation of the Estrogen Receptor Clone 6F11 with previously 510(k) approved devices (Ventana K110215; Dako K042884).
Additional inter-platform validation has shown excellent correlation between the different formats and the reference standard device.
This 510(k) submission describes the antibody as being available in the various formats. These formats include:
- Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ (PA0151, . PA0009), which is optimized for use on the Leica Biosystems Bond™ automated slide staining system (Bond III).
- Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, NovocastraTM . (NCL-L-ER-6F11, 1mL) for use on the Leica Biosystems Bond™ automated slide staining system (Bond III)
Reproducibility testing has additionally shown that all formats of the Estrogen Receptor Clone 6F11 perform adequately.
Therefore, based on the information provided in the premarket notification, Leica Newcastle concludes that both the Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ and the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ of estrogen receptor on the Bond III demonstrate similar performance to the predicate device K060227 for the indication for use, device design, material, operational principles and intended use.
{29}------------------------------------------------
Image /page/29/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the circle is a stylized symbol that resembles an eagle or bird-like figure.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
May 19, 2014
Leica Biosystems Richmond, Ltd Barbara Ann Conway-Myers, Ph.D. Senior Regulatory Affairs Specialist 5205 Route 12 Richmond, IL 60071
Re: K122556
Trade/Device Name: Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™
Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™M
Regulation Number: 21 CFR 864.1860 Regulation Name: Immunohistochemistry Reagents and Kits Regulatory Class: II Product Code: MYA Dated: April 8, 2014 Received: April 10, 2014
Dear Dr. Conway-Myers:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the
{30}------------------------------------------------
Page 2-Dr. Conway-Myers
electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Reena Philip -S
Reena Philip, Ph.D. Director Division of Molecular Genetics and Pathology Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{31}------------------------------------------------
Indications for Use
510(k) Number (if known) K122556
Device Name
Estrogen Receptor Clone 6F11 (ER 6F11)
· Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™;
· Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, NovocastraTM
Indications for Use (Describe)
Estrogen Receptor Clone 6F11 (ER 6F11) Mouse Monoclonal antibody is intended for laboratory use to qualitatively identify estrogen receptor (ER) antigen in sections of formalin fixed, paraffin embedded breast cancer tissue by immunohistochemistry methods. Estrogen Receptor Clone 6F11 specifically binds to the ER antigen located in the nucleus of ER positive normal and neoplastic cells.
Estrogen Receptor Clone 6F1 I is indicated as an aid in the management, prognosis and predication of therapy outcome of breast cancer. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by qualified pathologist.
Estrogen Receptor Clone 6F11 Ready-to-Use Primary Antibody for Bond™ and the Estrogen Receptor Clone 6F11 Liquid Concentrate Primary Antibody, Novocastra™ are optimized for use on the Leica Biosystems Bond III staining platform using the Bond Polymer Refine Detection Kit.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FOR FDA USE ONLY ON LINE OF A
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
Image /page/31/Picture/18 description: The image shows the text "Yun-fuHu-S" in a bold, sans-serif font. The letters are large and spaced closely together. The text appears to be a combination of uppercase and lowercase letters. The letters "fuHu" are partially obscured by a textured overlay.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
§ 864.1860 Immunohistochemistry reagents and kits.
(a)
Identification. Immunohistochemistry test systems (IHC's) are in vitro diagnostic devices consisting of polyclonal or monoclonal antibodies labeled with directions for use and performance claims, which may be packaged with ancillary reagents in kits. Their intended use is to identify, by immunological techniques, antigens in tissues or cytologic specimens. Similar devices intended for use with flow cytometry devices are not considered IHC's.(b)
Classification of immunohistochemistry devices. (1) Class I (general controls). Except as described in paragraphs (b)(2) and (b)(3) of this section, these devices are exempt from the premarket notification requirements in part 807, subpart E of this chapter. This exemption applies to IHC's that provide the pathologist with adjunctive diagnostic information that may be incorporated into the pathologist's report, but that is not ordinarily reported to the clinician as an independent finding. These IHC's are used after the primary diagnosis of tumor (neoplasm) has been made by conventional histopathology using nonimmunologic histochemical stains, such as hematoxylin and eosin. Examples of class I IHC's are differentiation markers that are used as adjunctive tests to subclassify tumors, such as keratin.(2) Class II (special control, guidance document: “FDA Guidance for Submission of Immunohistochemistry Applications to the FDA,” Center for Devices and Radiologic Health, 1998). These IHC's are intended for the detection and/or measurement of certain target analytes in order to provide prognostic or predictive data that are not directly confirmed by routine histopathologic internal and external control specimens. These IHC's provide the pathologist with information that is ordinarily reported as independent diagnostic information to the ordering clinician, and the claims associated with these data are widely accepted and supported by valid scientific evidence. Examples of class II IHC's are those intended for semiquantitative measurement of an analyte, such as hormone receptors in breast cancer.
(3) Class III (premarket approval). IHC's intended for any use not described in paragraphs (b)(1) or (b)(2) of this section.
(c)
Date of PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the Federal Food, Drug, and Cosmetic Act is required for any device described in paragraph (b)(3) of this section before this device may be commercially distributed. See § 864.3.